The polypill to prevent cardiovascular disease: physicians' perspectives

Area of Science:

• Cardiovascular Disease Prevention
• Public Health Strategies
• Pharmacology

Background:

• Polypills offer a single-pill combination for reducing cardiovascular disease (CVD) events.
• The polypill strategy involves population-based distribution (e.g., by age) rather than individual clinical decisions.
• Physician perspectives are crucial for the adoption of novel CVD prevention methods.

Purpose of the Study:

• To review recent studies on physicians' perspectives regarding the polypill.
• To assess physician willingness to prescribe polypills for primary and secondary CVD prevention.
• To identify factors influencing physician acceptance of polypill strategies.

Main Methods:

• Review of recent studies on physician perspectives on polypills.
• Analysis of survey data from physicians in Sri Lanka and the United States.
• Examination of factors influencing prescription likelihood, including risk reduction, side effects, and cost.

Main Results:

• High likelihood of polypill prescription for primary prevention (86% in Sri Lanka) and high-risk patients (83% in the US).
• Willingness to prescribe decreases for moderate-risk patients (62% in the US).
• Key prescribing factors include degree of risk reduction, side effects, and cost; low agreement on forgoing risk factor monitoring.

Conclusions:

• Physician acceptance of polypills is currently moderate to high, particularly for clinical application.
• Physician views may evolve towards accepting population-health approaches with emerging trial evidence.
• Physicians favor prescription-based access, with 89% of US physicians opposing over-the-counter availability.